阿替利珠单克隆抗体与贝伐珠单克隆抗体联合局部治疗在复发性肝癌肝移植前治疗中的临床疗效  

Clinical efficacy of atezolizumab plus bevacizumab combined with local therapy for the treat-ment of recurrent hepatocellular carcinoma before liver transplantation

作　　者：刘泽阳[1] 张廷啸 杜刚[1] 徐倩倩[1] 王建磊 夏童 刘铭坤 靳斌[1] Liu Zeyang;Zhang Tingxiao;Du Gang;Xu Qianqian;Wang Jianlei;Xia Tong;Liu Mingkun;Jin Bin(Department of Organ Transplantation,Qilu Hospital of Shandong University,Jinan 250012,China)

机构地区：[1]山东大学齐鲁医院器官移植科,济南250012

出　　处：《中华消化外科杂志》2022年第S01期20-24,共5页Chinese Journal of Digestive Surgery

基　　金：山东省重点研发计划(重大科技创新工程)(2022CXGC010502)。

摘　　要：通过局部治疗联合全身治疗,对复发性肝细胞癌患者进行肝移植前降期治疗,可控制肿瘤进展、减轻肿瘤负荷,从而降低肝移植等待期间患者的退出率,提供肿瘤学观察窗,使超米兰标准患者降期并获得更好的生存获益。笔者报道1例超米兰标准的肝癌术后复发患者接受阿替利珠单克隆抗体与贝伐珠单克隆抗体联合局部治疗后行肝移植的临床经验。其研究结果显示:患者达到病理学完全缓解,术后无排斥反应发生,预后良好,生命状况改善。Downstaging treatment by local therapy combined with systemic therapy before liver transplantation for patients with recurrent hepatocellular carcinoma(HCC)can control tumor progression and reduce tumor burden,which resulting in reducing the push-out rate of patients during the waiting period for liver transplantation,providing an oncological observation window,enabling patients of beyond Milan criteria downstaged with better survival benefit.The authors introduce the clinical experience of a case with recurrent HCC of beyond Milan criteria who under-went liver transplantation after receiving atezolizumab plus bevacizumab combined with local therapy.Results show the patient achieving pathological complete remission without postoperative rejection and obtaining a good prognosis with life status improved.

关 键 词：肝肿瘤 肝移植 术前降期 局部治疗 免疫治疗 移植排斥 

分 类 号：R735.7[医药卫生—肿瘤]